INIFY Laboratories

INIFY Laboratories EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of INIFY Laboratories (INIFY.OL) as of Oct 29, 2026 is -2.56. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -5.58 — a change of -54.10% (higher).

EV/FCF

-2.56

YoY

-54.10%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of INIFY Laboratories is 2025 -2.56 . EV/FCF (Enterprise Value to Free Cash Flow) of INIFY Laboratories was 2024 -5.58 . It decreases by -54.10% higher compared to the previous year.

The INIFY Laboratories EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2024
-5.58 SEK
Jan 1, 2025
-2.56 SEK
The INIFY Laboratories EV/FCF history
YEAREV/FCFYoY
-2.56-54.10%
-5.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

INIFY Laboratories Stock analysis

What does INIFY Laboratories do? INIFY Laboratories AB generates revenue through providing cancer diagnostics via digital pathology services. The company offers two primary services: Full pathology Reports signed by INIFY's subspecialized pathologists and Whole Slide Images (WSI) with Pathology Decision Support Tool (PDST) analysis results. These services target healthcare providers and institutions requiring efficient, AI-optimized diagnostics for prostate biopsies. The firm's Solna, Sweden laboratory handles the entire sample processing chain, from logistics to reporting, leveraging AI to enhance quality and speed. INIFY's workflow is fully digital and standardized, initially focusing on prostate diagnostics. The company's service model includes both direct reporting by INIFY pathologists and WSI generation with PDST analysis, catering to clients seeking streamlined pathology solutions. This approach differentiates INIFY from traditional pathology services by integrating AI support throughout the diagnostic process. The business originates from ContextVision, indicating a foundation in digital pathology innovation. INIFY's offerings are designed to optimize response times and quality in prostate biopsy analysis, serving healthcare organizations that require advanced diagnostic tools without managing the full pathology workflow internally. INIFY Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about INIFY Laboratories stock

EV/FCF (Enterprise Value to Free Cash Flow) of INIFY Laboratories is -2.56 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of INIFY Laboratories changed from -5.58 to -2.56, representing a -54.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) INIFY Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s INIFY Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — INIFY Laboratories

All Key Metrics — INIFY Laboratories